INFORMATION CONTAINED IN THIS FORM 6-K REPORT
This Amendment No. 1 to the 6-K of Kazia Therapeutics Limited (the “Company”) that was filed with the Securities and Exchange Commission on February 28, 2023 is being filed solely to include interactive data files in inline eXtensible Business Reporting Language (iXBRL) in connection with the Company’s interim results for the half-year ended December 31, 2022.
Attached as Exhibit 99.1 of this Report on Form 6-K is a copy of the Company’s interim results for the half-year ended December 31, 2022, which are hereby incorporated by reference into the Company’s registration statement on Form F-3 (File No. 333-259224).
EXHIBIT LIST
Exhibit | Description | |
99.1 | Half-year report for the six months ended December 31, 2022 | |
101.INS | XBRL Instance Document | |
101.SCH | XBRL Taxonomy Extension Schema Document | |
101.CAL | XBRL Taxonomy Extension Calculation Linkbase Document | |
101.DEF | XBRL Taxonomy Extension Definition Linkbase Document | |
101.LAB | XBRL Taxonomy Extension Label Linkbase Document | |
101.PRE | XBRL Taxonomy Extension Presentation Linkbase Document | |
104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
Kazia Therapeutics Limited (Registrant)
/s/ Karen Krumeich
Karen Krumeich
Chief Financial Officer
Date: 9 March 2023